X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
oncology (30) 30
index medicus (28) 28
female (24) 24
breast cancer (21) 21
middle aged (20) 20
adult (19) 19
aged (18) 18
cancer (17) 17
chemotherapy (15) 15
melanoma (13) 13
prognosis (13) 13
care and treatment (12) 12
clinical trials (10) 10
medicine (10) 10
research (10) 10
survival (10) 10
breast neoplasms - mortality (9) 9
melanoma - drug therapy (9) 9
research article (9) 9
young adult (9) 9
breast neoplasms - pathology (8) 8
disease-free survival (8) 8
health aspects (8) 8
male (8) 8
neoplasm staging (8) 8
patients (8) 8
breast neoplasms - drug therapy (7) 7
cancer patients (7) 7
chemotherapy, adjuvant (7) 7
gene expression (7) 7
immunohistochemistry (7) 7
medical research (7) 7
metastasis (7) 7
patient outcomes (7) 7
risk factors (7) 7
aged, 80 and over (6) 6
analysis (6) 6
immunotherapy (6) 6
medical prognosis (6) 6
medicine & public health (6) 6
mutation (6) 6
paclitaxel (6) 6
pathology (6) 6
risk (6) 6
therapy (6) 6
treatment outcome (6) 6
tumors (6) 6
abridged index medicus (5) 5
anthracyclines (5) 5
biomarkers (5) 5
cancer therapies (5) 5
drug dosages (5) 5
erbb-2 protein (5) 5
hospitals (5) 5
immunology (5) 5
laboratories (5) 5
melanoma - genetics (5) 5
metastases (5) 5
metastatic melanoma (5) 5
oncology, experimental (5) 5
science (5) 5
studies (5) 5
survival analysis (5) 5
adjuvant treatment (4) 4
angiogenesis (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
article (4) 4
breast (4) 4
breast neoplasms - genetics (4) 4
breast neoplasms - therapy (4) 4
breast tumors (4) 4
cancer treatment (4) 4
cancers and neoplasms (4) 4
cobimetinib (4) 4
dense sequential chemotherapy (4) 4
double-blind (4) 4
epidemiology (4) 4
epidermal growth factor (4) 4
epirubicin (4) 4
interferon (4) 4
interferon-alpha - therapeutic use (4) 4
mek inhibition (4) 4
melanoma - pathology (4) 4
multidisciplinary sciences (4) 4
open-label (4) 4
phase-iii (4) 4
receptors (4) 4
retrospective studies (4) 4
risk groups (4) 4
risk-factors (4) 4
skin neoplasms - drug therapy (4) 4
skin neoplasms - genetics (4) 4
amplification (3) 3
arthralgia (3) 3
biology and life sciences (3) 3
brca1 (3) 3
breast neoplasms - diagnosis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 436 - 444
Summary Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-free survival... 
Hematology, Oncology and Palliative Medicine
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 603 - 615
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2019, Volume 119, pp. 97 - 106
Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for V600-mutant metastatic... 
Encorafenib | Vemurafenib | Safety | Binimetinib | Melanoma | TRAMETINIB | INHIBITOR-ASSOCIATED RETINOPATHY | OPEN-LABEL | BRAF | COMBINED DABRAFENIB | MEK INHIBITOR | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | Complications and side effects
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 4, pp. 320 - 330
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2014, Volume 9, Issue 3, p. e91407
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2018, Volume 13, Issue 7, p. e0200302
Several studies support an important role of angiogenesis in breast cancer growth and metastasis. The main objectives of the study were to investigate the... 
CLINICAL ONCOLOGY/COLLEGE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | LYMPHANGIOGENESIS | FACTOR EXPRESSION | VEGF-C | TUMOR ANGIOGENESIS | CARCINOMA | AMERICAN SOCIETY | ENDOTHELIAL GROWTH-FACTOR | Neovascularization, Pathologic - mortality | Neovascularization, Pathologic - diagnosis | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor Receptor-3 - metabolism | Breast - metabolism | Breast Neoplasms - metabolism | Young Adult | Breast Neoplasms - pathology | Vascular Endothelial Growth Factor C - metabolism | Adult | Breast Neoplasms - mortality | Female | Aged | Breast Neoplasms - diagnosis | Neovascularization, Pathologic - metabolism | Breast - pathology | Proteins | Immunohistochemistry | Care and treatment | Cancer patients | Chemotherapy | Patient outcomes | Breast cancer | Vascular endothelial growth factor | Cancer | Health sciences | Laboratories | C protein | Oncology | Paraffin | Kinases | Subgroups | Metastases | Angiogenesis | Signal transduction | Receptors | Epidermal growth factor | Paraffins | Medical research | Parameters | Statistical tests | Gene expression | Patients | ErbB-2 protein | Survival | Vascular endothelial growth factor receptors | Medicine | Pathology | Gene amplification | Hospitals | Anthracycline | Medical prognosis | Biomarkers | Breast | Tumors
Journal Article
by Gershenwald, Jeffrey E and Scolyer, Richard A and Hess, Kenneth R and Sondak, Vernon K and Long, Georgina V and Ross, Merrick I and Lazar, Alexander J and Faries, Mark B and Kirkwood, John M and McArthur, Grant A and Haydu, Lauren E and Eggermont, Alexander M. M and Flaherty, Keith T and Balch, Charles M and Thompson, John F and Gershenwald, Jeffrey E and Scolyer, Richard A and Atkins, Michael B and Balch, Charles M and Barnhill, Raymond L and Bilimoria, Karl Y and Buzaid, Antonio C and Byrd, David R and Cochran, Alistair J and Eggermont, Alexander M. M and Elder, David E and Faries, Mark B and Flaherty, Keith T and Garbe, Claus and Gardner, Julie M and Gimotty, Phyllis A and Halpern, Allan C and Haydu, Lauren E and Hess, Kenneth R and Johnson, Timothy M and Kirkwood, John M and Lazar, Alexander J and Lee, Anne W. M and Long, Georgina V and McArthur, Grant A and Mihm Jr, Martin C and Prieto, Victor G and Ross, Merrick I and Sober, Arthur J and Sondak, Vernon K and Thompson, John F and Wong, Sandra L and Delman, Keith A and Santinami, Mario and Maurichi, Andrea and Nagore, Eduardo and Faries, Mark B and Thompson, John F and Scolyer, Richard A and McArthur, Grant A and Gyorki, David E and Henderson, Michael and Stratigos, Alexander J and Gogas, Helen and Gershenwald, Jeffrey E and Haydu, Lauren E and Rossi, Carlo Riccardo and Sommariva, Antonio and American Joint Comm Canc Melanoma and Int Melanoma Database Discovery and for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform
CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 11/2017, Volume 67, Issue 6, pp. 472 - 492
Journal Article